91ÖÆÆ¬³§

Ochre News

NEWS COVERAGE

16 UK startups (not from London) to watch, according to investors

Dr. Quin Wills at SXSW London 2025: Can AI Turn Animal Testing Human

25 European Startups to watch

The superpowers of weight-loss jabs extend to our livers

AI deals show no sign of slowing

91ÖÆÆ¬³§ appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director

The Pharma Letter Podcast — Episode 33 — 91ÖÆÆ¬³§ Boehringer and GSK are betting on Ochre

91ÖÆÆ¬³§, addressing the complexities of liver disease

Podcast: 91ÖÆÆ¬³§â€™s Approach To Precision Medicine In Liver Treatment

Changing the Odds in Liver Disease with Computational Biology and Human-first Models

Top 10 Spatial Biology Companies of 2024

BBC Click

Leading innovation: 10 promising European startups focusing on biopharmaceuticals

How to make your organs last longer | Quin Wills | TEDxNoVA

Drug discovery: 20 startups to watch

GSK signs AI pact with Ochre to pinpoint source of liver diseases

The Biotech Startups Podcast: Quin Wills

91ÖÆÆ¬³§ announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease

Boehringer signs $1.3B deal with RNA biotech 91ÖÆÆ¬³§ to team up against MASH

Boehringer Ingelheim inks chronic liver disease research pact with 91ÖÆÆ¬³§

UK biotech signs $1bn deal to develop liver disease drugs

Podcast: Unlock the potential of complex human liver data

UK startups are built on immigrant talent, the UK will fail if it forgets this

Future of liver drugs – better AI or better data?

91ÖÆÆ¬³§: fully human, super speedy liver drug development

Exploring liver disease therapies 

91ÖÆÆ¬³§ with CEO/Co-founder Jack O’Meara and liver expert Dr Scott Friedman, Mount Sinai

Revolutionising Liver Transplants: Can Phenotyping Drive Biotech Transformation in Healthcare?

Business of Biotech with 91ÖÆÆ¬³§’s Quin Wills, M.D., PH.D

91ÖÆÆ¬³§ CEO named on Forbes 30 Under 30 Europe

18 European techbio startups to watch — according to investors

The intersection between healthcare, technology, strategy and impact – Interview with 91ÖÆÆ¬³§â€™s CEO and co-founder Jack O’Meara

AI and computational biology transforming chronic liver disease research 

‘I wanted to do something in health but I didn’t want to be a doctor’: 91ÖÆÆ¬³§ founder Jack O’Meara

91ÖÆÆ¬³§ Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

Five Spatial Genomics Up-and-Coming Firms

Jeremy Hunt’s R&D shake-up divides UK small businesses

Oxford biotech raises funds to make RNA treatments for liver disease

RNA therapies startup 91ÖÆÆ¬³§ lands $30M to take on chronic liver disease

A liver disease upstart with some global connections and a new R&D strategy reaps a $30M launch round

Skydivers raise almost £10,000 for children at Helen & Douglas House

A New Era in European Life Sciences Investment

Chirps, chats and Clubhouses: First-time biotech founders turn to social media for advice, investors and recruitment

‘Day job and a gay job’: LGBTQ+ leaders in biopharma want those who look, talk and love like them to be seen and counted

Biotech Startup 91ÖÆÆ¬³§ Lands Seed Financing to Combat Liver Diseases

Biotech looks to upset the preclinical model for liver drug development, and now it’s gearing up for the clinic

Lyfebulb and CSL Behring Announce the Finalists for the 2021 Transplant Innovation Challenge

New hope for beating the hidden fatty liver epidemic, a silent killer

Entrepreneur First’s Latest European Cohort Revealed, With Plenty Of Biotech Startups On Show

All the companies from Y Combinator’s W20 Demo Day, Part IV: Healthcare, Biotech, Fintech and Nonprofits

Join our Mailing List